Long interspersed nuclear element-1 (LINE-1 or L1), the most abundant family of autonomous retrotransposons occupying over 17% of human DNA, is epigenetically silenced in normal tissues by the mechanisms involving p53 but is frequently derepressed in cancer, suggesting that L1-encoded proteins may act as tumor-associated antigens recognized by the immune system. In this study, we established an immunoassay to detect circulating autoantibodies against L1 proteins in human blood. Using this assay in >2,800 individuals with or without cancer, we observed significantly higher IgG titers against L1-encoded ORF1p and ORF2p in patients with lung, pancreatic, ovarian, esophageal, and liver cancers than in healthy individuals. Remarkably, elevated levels of anti-ORF1p-reactive IgG were observed in patients with cancer with disease stages 1 and 2, indicating that the immune response to L1 antigens can occur in the early phases of carcinogenesis. We concluded that the antibody response against L1 antigens could contribute to the diagnosis and determination of immunoreactivity of tumors among cancer types that frequently escape early detection. SIGNIFICANCE: The discovery of autoantibodies against antigens encoded by L1 retrotransposons in patients with five poorly curable cancer types has potential implications for the detection of an ongoing carcinogenic process and tumor immunoreactivity.
Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans.
循环抗体对人类LINE-1抗原的抗癌意义
阅读:8
作者:Vylegzhanina Alexandra V, Bespalov Ivan A, Novototskaya-Vlasova Ksenia A, Hall Brandon M, Gleiberman Anatoli S, Yu Han, Leontieva Olga V, Leonova Katerina I, Kurnasov Oleg V, Osterman Andrei L, Dy Grace K, Komissarov Alexey A, Vasilieva Elena, Gehlhausen Jeff, Iwasaki Akiko, Ambrosone Christine B, Tsuji Takemasa, Matsuzaki Junko, Odunsi Kunle, Andrianova Ekaterina L, Gudkov Andrei V
| 期刊: | Cancer Research Communications | 影响因子: | 3.300 |
| 时间: | 2023 | 起止号: | 2023 Nov 8; 3(11):2256-2267 |
| doi: | 10.1158/2767-9764.CRC-23-0289 | 研究方向: | 肿瘤 |
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
